Privately-held Swiss drugmaker Ferring Pharmaceuticals has appointed Professor Klaus Dugi as executive vice president and chief medical officer (CMO), effective immediately.
He will be responsible for global medical affairs, quality assurance and pharmacovigilance. In addition, he will also be a member of the Ferring executive board.
Prior to this role, Prof Dugi held various leadership roles at Germany’s Boehringer Ingelheim, including vice president global medical affairs, CMO, and, most recently, managing director UK & Ireland.
“Making the industry more patient-centric has always been a top priority for Prof Dugi, and this is perfectly aligned with our company philosophy and commitment to solving unmet patient needs, particularly in the area of reproductive and maternal health,” said Michel Pettigrew, president of the executive board and chief operating officer, Ferring Pharmaceuticals.
A Professor of Medicine, with a speciality in internal medicine, Prof Dugi continues to teach medicine at Heidelberg University, Germany. He also spent four years carrying out research at the US National Institutes of Health (NIH) and has published more than 70 manuscripts in peer-reviewed journals including The Lancet and Diabetes.
Source: The Pharma Letter
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.